GFH018

DRUG3 trials

Sponsors

Genfleet Therapeutics (Shanghai) Inc., Zhejiang Genfleet Therapeutics Co., Ltd.

Conditions

Advanced Solid TumorNSCLC, Stage III

Phase 1

A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors

CompletedNCT04914286

Genfleet Therapeutics (Shanghai) Inc.Advanced Solid Tumor

Start: 2021-10-20End: 2023-12-31Updated: 2025-05-14

A Study of GFH018 in Patients With Advanced Solid Tumors

CompletedNCT05051241

Zhejiang Genfleet Therapeutics Co., Ltd.Advanced Solid Tumor

Start: 2019-08-30End: 2022-08-11Updated: 2024-03-01

Phase 2

A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

CompletedNCT05386888

Genfleet Therapeutics (Shanghai) Inc.NSCLC, Stage III

Start: 2022-09-09End: 2023-12-31Updated: 2025-10-02

Related Papers

First-in-human study of GFH018, a small molecule inhibitor of transforming growth factor-β receptor I inhibitor, in patients with advanced solid tumors

BMC Cancer2024-04-1013 citations

A phase Ib/II study of GFH018 in combination with toripalimab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).

Journal of Clinical Oncology2023-06-0120 citations

GFH018, a small molecular inhibitor targeting TGF-βRI kinase, in patients with advanced solid tumors: Final results of the phase I study.

Journal of Clinical Oncology2023-06-013 citations